Last reviewed · How we verify
Placebo foam
Placebo foam is an inert formulation with no active pharmaceutical ingredient, serving as a control or vehicle for topical application.
At a glance
| Generic name | Placebo foam |
|---|---|
| Also known as | placebo |
| Sponsor | Beijing Dayspring Pharmaceutical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
As a placebo product, it contains no active drug substance and exerts no pharmacological effect. It is used in clinical research and marketed contexts as a comparator or base formulation. The foam vehicle may provide physical benefits such as coverage or moisturization, but these are non-pharmacological.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia (PHASE3)
- Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (PHASE2)
- Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery (PHASE4)
- Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations (PHASE2)
- EFFECT OF HAMMAM EXPERIENCE ON GENERAL HEALTH AND PERCEIVED WELL-BEING (NA)
- Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo (PHASE4)
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo foam CI brief — competitive landscape report
- Placebo foam updates RSS · CI watch RSS
- Beijing Dayspring Pharmaceutical Technology Co., Ltd portfolio CI